2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12319A
    Cardiogenol C hydrochloride 1049741-55-0 99.79%
    Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC50=100 nM). Cardiogenol C hydrochloride also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C hydrochloride is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models.
    Cardiogenol C hydrochloride
  • HY-123468
    HA-1004 91742-10-8 99.04%
    HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models.
    HA-1004
  • HY-126195
    Fluoflavine 531-46-4 ≥98.0%
    Fluoflavine (ML-090) is a selective NOX1 inhibitor with an IC50 of 90 nM. Fluoflavine has >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50>10 μM). ML-090 has an IC50 of 360 nM in HEK293 cells.
    Fluoflavine
  • HY-126486
    AVE1231 767334-89-4 98.61%
    AVE1231 (A293) is a dual-pore potassium channel TASK-1 inhibitor. AVE1231 blocks carbamoylcholine chloride (HY-B1208)-activated IKACh (IC50=8.4 μM). AVE1231 can be used in the study of arrhythmias and atrial fibrillation.
    AVE1231
  • HY-12753A
    Debutyldronedarone hydrochloride 197431-02-0 98.32%
    Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α1 (TRα1) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα1 and TRβ1 by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic.
    Debutyldronedarone hydrochloride
  • HY-130345
    PAF (C18) 74389-69-8 99.00%
    C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension.
    PAF (C18)
  • HY-133149
    Lp-PLA2-IN-3 2196245-16-4 99.94%
    Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).
    Lp-PLA2-IN-3
  • HY-13463B
    Avatrombopag hydrochloride 570403-17-7
    Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
    Avatrombopag hydrochloride
  • HY-135356
    m-Nifedipine 21881-77-6
    m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
    m-Nifedipine
  • HY-135517
    RXP470.1 891198-31-5 99.60%
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification.
    RXP470.1
  • HY-138201
    IM-93 1173657-73-2 99.00%
    IM-93 inhibits ferroptosis and NETosis with an IC< sub>50 of 0.45 µM for cell death inhibition.
    IM-93
  • HY-138686
    GPR30 agonist-1 415919-74-3 98.62%
    GPR30 agonist-1 is a G protein-coupled receptor 30 (GPR30) agonist. GPR30 agonist-1 exerts vasorelaxant effects.
    GPR30 agonist-1
  • HY-138822
    2,3-Diphospho-D-glyceric acid pentasodium salt 102783-53-9
    2,3-Diphospho-D-glyceric acid pentasodium salt is a highly anionic polyphosphorus compound. 2,3-Diphospho-D-glyceric acid is present in the concave center of red blood cells, it binds hemoglobin to reduce its oxygen affinity. 2,3-Diphospho-D-glyceric acid is an endogenous, selective inhibitor of vascular calcification (VC) and significantly delays the formation of crystalline calpain particles (CPP). 2,3-Diphospho-D-glyceric acid also inhibits calcification in mouse vascular smooth muscle cell line (MOVAS) without cytotoxic effects.
    2,3-Diphospho-D-glyceric acid pentasodium salt
  • HY-141714
    SBC-115337 423148-46-3 98.02%
    SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC50 value of 0.5 μM.
    SBC-115337
  • HY-144549
    LXR agonist 1 1779524-90-1 99.95%
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.
    LXR agonist 1
  • HY-144652
    IDO1-IN-19 2328099-11-0 98.82%
    IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases.
    IDO1-IN-19
  • HY-145197
    MPO-IN-3 1435469-45-6 99.17%
    MPO-IN-3 is a potent myeloperoxidase (MPO) inhibitor (WO2013068875A1, example 191). Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the peroxidase superfamily.
    MPO-IN-3
  • HY-145604
    Vicasinabin 1433361-02-4 98.37%
    Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization.
    Vicasinabin
  • HY-148707
    SphK1&2-IN-1 1415662-57-5 99.33%
    SphK1&2-IN-1 is a SphK inhibitor targeting to SphK1 and SphK2. SphK1&2-IN-1 has thermal stability.
    SphK1&2-IN-1
  • HY-14928A
    Lobeglitazone sulfate 763108-62-9 99.63%
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.
    Lobeglitazone sulfate
Cat. No. Product Name / Synonyms Application Reactivity